Skip to main content

Table 1 The clinical, basal endocrine and metabolic characteristics of the study population

From: Growth hormone alleviates oxidative stress and improves the IVF outcomes of poor ovarian responders: a randomized controlled trial

  POR-GH (n = 52) POR-C (n = 53) Non-POR (n = 58)
Age (years) ab 38.41 ± 2.91 38.20 ± 2.79 29.56 ± 3.12
Infertility duration (years) 4.57 ± 3.14 4.39 ± 3.22 3.47 ± 2.22
Risk factors for POR cycle (n) ab 20 18 0
Abnormal ORT cycle (n) ab 39 32 0
Previous POR cycle (n) ab 21 23 0
BMI (kg/m2) 22.09 ± 1.73 22.62 ± 2.73 22.19 ± 2.67
FSH (mIU/mL) ab 11.49 ± 2.94 10.97 ± 2.75 5.89 ± 1.76
LH (mIU/mL) 4.59 ± 1.83 4.36 ± 1.57 4.29 ± 1.45
FSH / LH ratio ab 2.74 ± 1.57 2.53 ± 1.68 1.38 ± 0.75
E2 (pg/mL) ab 75.98 ± 34.05 72.34 ± 26.87 40.62 ± 11.19
P (ng/mL) 0.64 ± 0.39 0.54 ± 0.35 0.55 ± 0.20
TT (ng/mL) 0.37 ± 0.19 0.41 ± 0.20 0.43 ± 0.15
AMH (ng/mL) ab 0.88 ± 0.67 0.81 ± 0.41 3.50 ± 1.91
PRL (μIU/mL) 162.59 ± 50.19 171.25 ± 52.32 163.51 ± 45.79
HOMA-IR 1.68 ± 1.25 1.71 ± 1.34 1.67 ± 1.33
AFC ab 4.12 ± 1.71 4.06 ± 2.11 15.30 ± 4.56
  1. Note: Data are presented as the mean ± SD or number. BMI body mass index, FSH follicle-stimulating hormone, LH luteinizing hormone, E2 oestradiol, P progesterone, TT total testosterone, AMH anti-Mullerian hormone, PRL prolactin, HOMA-IR homeostatic model assessment of insulin resistance, AFC antral follicle count
  2. a P < 0.05 the POR-GH group versus the non-POR group
  3. b P < 0.05 the POR-C group versus the non-POR group